文献速递白血病

维奈克拉联合PEG化天冬酰胺酶治疗复杂核型急性髓系白血病

Venetoclax and pegcrisantaspase for complex karyotype acute myeloid leukemia.
PubMed 文献 · Leukemia · 2020-11-16

复杂核型急性髓系白血病(CK-AML)目前疗效差,亟需新方案。本研究在体外和体内证实,BCL-2抑制剂维奈克拉(Ven)与PEG化天冬酰胺酶(PegC)联合具有协同抗白血病活性;在患者来源的CK-AML异种移植模型中,Ven-PegC较单药及临床常用的Ven-阿扎胞苷方案更有效,并揭示PegC耗竭谷氨酰胺抑制4EBP1磷酸化、降低MCL-1翻译的机制。

要点

  • Ven-PegC在CK-AML体外和体内均显示协同抗白血病活性。
  • 在患者来源CK-AML异种移植中,Ven-PegC优于单药和Ven-阿扎胞苷。
  • 机制涉及谷氨酰胺耗竭抑制4EBP1磷酸化并降低MCL-1翻译。

核心结论

  • Ven-PegC在CK-AML中具有协同抗白血病活性,支持开展复发/难治CK-AML临床试验。

研究设计与样本

  • 体外研究使用多种AML细胞系和患者来源原代CK-AML细胞。
  • 体内研究使用患者来源CK-AML异种移植模型。

主要发现

  • Ven-PegC在体外抑制多种AML细胞系和患者来源原代CK-AML细胞生长。
  • 在患者来源CK-AML异种移植中,Ven-PegC较单药更强降低白血病负荷并改善生存。
  • 在CK-AML体内模型中,Ven-PegC优于临床使用的Ven-阿扎胞苷联合方案。
  • Ven-PegC通过谷氨酰胺耗竭增强eIF4E-4EBP1在帽结合复合物上的相互作用,降低体外细胞MCL-1蛋白水平。
  • 体内Ven-PegC完全耗竭血浆谷氨酰胺和天冬酰胺,并抑制mRNA翻译和细胞蛋白合成。

临床怎么用

  • Ven-PegC为复发/难治CK-AML提供了一种机制合理且两药均已用于急性白血病治疗的候选方案。

局限性

  • 研究为临床前体外和体内实验,尚未在患者中验证疗效与安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Complex karyotype acute myeloid leukemia (CK-AML) has a dismal outcome with current treatments, underscoring the need for new therapies. Here, we report synergistic anti-leukemic activity of the BCL-2 inhibitor venetoclax (Ven) and the asparaginase formulation Pegylated Crisantaspase (PegC) in CK-AML in vitro and in vivo. Ven-PegC combination inhibited growth of multiple AML cell lines and patient-derived primary CK-AML cells in vitro. In vivo, Ven-PegC showed potent reduction of leukemia burden and improved survival, compared with each agent alone, in a primary patient-derived CK-AML xenograft. Superiority of Ven-PegC, compared to single drugs, and, importantly, the clinically utilized Ven-azacitidine combination, was also demonstrated in vivo in CK-AML. We hypothesized that PegC-mediated plasma glutamine depletion inhibits 4EBP1 phosphorylation, decreases the expression of proteins such as MCL-1, whose translation is cap dependent, synergizing with the BCL-2 inhibitor Ven. Ven-PegC treatment decreased cellular MCL-1 protein levels in vitro by enhancing eIF4E-4EBP1 interaction on the cap-binding complex via glutamine depletion. In vivo, Ven-PegC treatment completely depleted plasma glutamine and asparagine and inhibited mRNA translation and cellular protein synthesis. Since this novel mechanistically-rationalized regimen combines two drugs already in use in acute leukemia treatment, we plan a clinical trial of the Ven-PegC combination in relapsed/refractory CK-AML.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Emadi A, Kapadia B, Bollino D, et al. Venetoclax and pegcrisantaspase for complex karyotype acute myeloid leukemia. Leukemia. 2020. PMID: 33199836. doi:10.1038/s41375-020-01080-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。